Canonical: https://ownershiptrace.com/13f/companies/105570

# Who owns BioStem Technologies, Inc. (BSEM)? Elite investor 13F holders

1 tracked elite investors reported holding BioStem Technologies, Inc as of 2026-09-30, including Anson Funds. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

1 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft…

## Reported holders and securities, including exits (up to 20)

| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|  --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [Anson Funds](https://ownershiptrace.com/13f/investors/117) | BioStem Technologies Inc | SHARE | 2026-09-30 | 2026-11-13 00:00:00 | 1215398.00 USD | 367648.000000 | Shares | buy | [Original filing](https://www.sec.gov/Archives/edgar/data/1491072/0001193125-26-460605-index.html) |

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

[How to read the data](https://ownershiptrace.com/docs#reading-the-data) · [Disclaimer](https://ownershiptrace.com/disclaimer)
